Compare CSTE & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | ACET |
|---|---|---|
| Founded | 1987 | 1947 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 71.3M |
| IPO Year | 2012 | N/A |
| Metric | CSTE | ACET |
|---|---|---|
| Price | $1.74 | $8.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $136.00 |
| AVG Volume (30 Days) | 142.0K | ★ 201.2K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $400,656,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $7.15 |
| 52 Week High | $4.67 | $17.76 |
| Indicator | CSTE | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 97.99 |
| Support Level | $1.65 | $0.47 |
| Resistance Level | $2.05 | $8.84 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | -0.01 | 0.93 |
| Stochastic Oscillator | 46.91 | 94.87 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.